tapebrief
LH · Q1 2026

LH · Q2 2026 Earnings

Bullish

Labcorp

Reported July 30, 2026

30-second summary

Q2 revenue grew 5.8% YoY to $3.73B, non-GAAP EPS beat consensus by 4.6% at $4.99, and management raised the FY2026 EPS midpoint $0.30 and revenue growth midpoint 30bps — the second consecutive raise but the first one that's clearly funded by top-line momentum rather than margin discipline alone. The signal that matters: Diagnostics organic growth recovered to 3.6% from Q1's 2.9%, and Biopharma's segment growth guide was raised 110bps at midpoint on backlog conversion strength, invalidating the "volume thesis is dead" concern from last quarter. Free cash flow guide was held flat despite the EPS raise, and TTM book-to-bill improved to 1.03 — still the fourth consecutive sub-1.10 print, keeping the structural-cap question open.

Headline numbers

EPS

Q2 FY2026

$4.99

+4.6% vs est.

Revenue

Q2 FY2026

$3.73B

+5.8% YoY

+0.6% vs est.

Gross margin

Q2 FY2026

29.8%

Free cash flow

Q2 FY2026

$0.31B

Operating margin

Q2 FY2026

12.1%

Key financials

Q2 FY2026
MetricQ2 FY2026Q2 FY2025YoYQ1 FY2026QoQ
Revenue$3.73B$3.53B+5.7%$3.54B+5.4%
EPS$4.99$4.35+14.7%$4.25+17.4%
Gross margin29.8%29.6%+20bps28.7%+110bps
Operating margin12.1%11.2%+90bps10.8%+130bps
Free cash flow$0.31B$0.54B-42.2%$0.07B+345.2%

Guidance

Labcorp raised full-year EPS guidance by $0.30 at midpoint and revenue growth by 30 basis points, driven by stronger-than-expected Q2 execution and upward momentum in Biopharma Laboratory Services; Free Cash Flow guidance maintained.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Changes to prior guidance

MetricPeriodPrior guideNew guideΔResult
Adjusted EPS
FY2026
$17.70 to $18.35$18.10 to $18.55+$0.30 at midpoint (prior $18.025 → current $18.325)Raised
Revenue growth
FY2026
5.0% to 6.1%5.4% to 6.3%+30 bps at midpoint (prior 5.55% → current 5.85%)Raised
Diagnostics Laboratories growth
FY2026
5.1% to 5.9%5.3% to 6.0%+20 bps at midpoint (prior 5.50% → current 5.65%)Raised
Biopharma Laboratory Services growth
FY2026
3.8% to 5.4%5.5% to 6.5%+110 bps at midpoint (prior 4.60% → current 6.00%)Raised
Diagnostics Laboratories revenue
FY2026
$11.43 billion to $11.52 billion$11.450 billion to $11.532 billion+$0.010-0.012B range narrowed and raised slightly (midpoint prior $11.475B → current $11.491B)Raised
Biopharma Laboratory Services revenue
FY2026
$3.22 billion to $3.27 billion$3.269 billion to $3.300 billion+$0.049-0.030B (midpoint prior $3.245B → current $3.285B)Raised

Reaffirmed unchanged this quarter: Free Cash Flow ($1.24 billion to $1.36 billion)

Segment KPIs

Q2 FY2026
SegmentQ2 FY2026Q2 FY2025YoY
Diagnostics Laboratories$2.901B$2.75B+5.5%
Biopharma Laboratory Services$0.836B$0.785B+6.5%
Diagnostics Organic Growth3.6%——
Biopharma Organic Growth6.2%——

Other KPIs

Q2 FY2026
SegmentQ2 FY2026Q2 FY2025YoY
Diagnostics Laboratories Adjusted Operating Margin18.0%——
Biopharma Laboratory Services Adjusted Operating Margin17.0%——
Consolidated Adjusted Operating Margin15.8%——
Biopharma TTM Book to Bill1.03——
Biopharma Backlog$8.73 billion——
Biopharma Next Twelve Months Backlog Conversion$2.75 billion——

Management tone

Organic volume re-acceleration → navigating FX and PAMA headwinds → operational candor and strategic rebuild → confidence on margin while volume softens → execution validates the rebuild.

[Multi-quarter tone shift analysis requires transcript-based inputs; no earnings call transcript was available for this print. The press release commentary is limited to the CEO quote below.]

The only prepared commentary available is Adam Schechter's press-release statement: "Labcorp delivered another very strong quarter, with 6% revenue growth, significant margin expansion, and double-digit adjusted EPS growth. Our performance and continued execution position us well to deliver sustainable growth and long-term value for customers and shareholders." That's a materially more confident tone than Q1's framing, and the guide raise mechanics back it up — the Biopharma floor moved 170bps, which is not a hedge, it's a commitment. The rebuild-year framing from Q4 FY2025 is being repositioned as an execution-year narrative, but investors should mark that the flat FCF guide alongside the $0.30 EPS raise means the harvest phase management previewed for late-2026 has not yet arrived in cash conversion.

Answers to last quarter's watch list

Q2 FY2026 Diagnostics organic growth — needs to recover meaningfully above 3.5% — Diagnostics organic growth printed 3.6%, clearing the 3.5% threshold by a whisker. Total Diagnostics revenue grew 5.5% YoY with segment adj. operating margin expanding to 18.0% (from 16.6% in Q1). The volume-acceleration thesis is not restored to Q2 FY2025's 4.5%+ pace, but the Q1 slide was arrested and the FY Diagnostics growth guide was raised 20bps at midpoint. The read is cautiously positive — enough to keep the specialty-testing narrative investable for another quarter, but not enough to declare the volume engine fully back.
Resolved positively
BLS adj. operating margin post-ED restructuring — BLS margin recovered to 17.0%, up 150bps from Q1's 15.5% and effectively matching Q4 FY2025's 17.2%. Combined with Biopharma organic growth of 6.2% (up from 3.7% in Q1) and the 110bps FY segment growth guide raise, the restructuring math is validated as advertised. This is the cleanest positive from the print.
Resolved positively
Biopharma TTM book-to-bill — fourth consecutive sub-1.10 print would force a structural reset on BLS — TTM book-to-bill came in at 1.03, one tick below Q1's 1.04 and the fourth consecutive sub-1.10 print. Backlog held at $8.73B (roughly flat) with NTM convertible backlog at $2.75B. The current-quarter revenue and guide-raise strength provides tactical offset, but the leading indicator continues to signal that FY2027+ BLS growth is structurally capped in the mid-single digits at best.
Resolved negatively
PAMA / Results Act resolution — No new disclosure in the press release. Management did not publicly comment on CBO scoring, CMS technical assessment, or the count of reporting labs. The FY2026 guide raise implicitly assumes no material change in the reimbursement outlook, which is consistent with prior framing but provides no new information on the FY2027 setup.
Continue monitoring
Free cash flow conversion in Q2 FY2026 — Q2 FCF came in at $313.9M, materially better than Q1's $70.5M — H1 FCF is now $384M against the FY guide midpoint of $1.30B, implying $916M needed in H2, which is heavy but achievable given seasonal patterns. FY FCF guide was held flat despite the $0.30 EPS raise, confirming capex is running hot enough to absorb the P&L upside. On track, but the guide freeze while EPS moved up is a subtle tell that cash conversion is not accelerating in line with earnings. Status: Resolved positively (on Q2 alone); FY cash conversion trajectory: Continue monitoring

What to watch into next quarter

Q3 FY2026 Diagnostics organic growth — needs to hold at or above 3.6% to confirm the trend recovery is real. Q2's 3.6% cleared the watch threshold but only by a tick; another quarter at 3.6%+ is required to invalidate the Q1 deceleration read as a one-quarter fluke rather than a structural slowdown.

Biopharma TTM book-to-bill — recovery above 1.05 would ease the structural-cap concern; another sub-1.05 print would harden it. Four consecutive sub-1.10 prints is now the dominant BLS pattern, and the strong current-quarter organic growth (6.2%) can only mask the leading-indicator weakness for so long.

H2 FCF ramp — Q3 and Q4 combined need to deliver $916M to hit the FY guide midpoint of $1.30B. Watch whether Q3 delivers at least $400M; anything materially below that puts a Q4 guide cut on the table.

BLS revenue growth into Q3 against the new FY floor of 5.5%. With the Q2 organic acceleration to 6.2% and the segment growth guide floor raised 170bps, a Q3 BLS growth print below the new FY implied trajectory would signal the raise was aggressive.

Any incremental commentary on PAMA / Results Act / CBO scoring. With no press-release update this quarter and the FY2027 reimbursement setup still open, watch for management commentary at investor conferences or on the Q3 call. A concrete legislative or delay outcome would remove the largest overhang from the FY2027 model.

Sources

  1. Labcorp Q2 FY2026 Form 8-K Exhibit 99.1 — https://www.sec.gov/Archives/edgar/data/920148/000092014826000162/form8-kexhibit9912q26.htm
  2. Labcorp Q1 FY2026 brief (Tapebrief internal — prior coverage)
  3. Labcorp Q4 FY2025 brief (Tapebrief internal — prior coverage)
  4. Labcorp Q3 FY2025 brief (Tapebrief internal — prior coverage)
  5. Labcorp Q2 FY2025 brief (Tapebrief internal — prior coverage)

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.